Abstract
Background: A respiratory syncytial virus (RSV) vaccine, eliciting active immunity could significantly impact child health. This study evaluated 3 intranasal live-attenuated candidate RSV vaccines, RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 to placebo. Methods: Healthy, RSV-seronegative children aged 6–24 monthswere randomized to receive 1 of 3 candidate vaccines or placebo. Participants were monitored for vaccine reactogenicity and RSV serum antibodies. Results: Between years 2019 and 2023, 67 participants were randomized, 20 each to RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and placebo and 7 to RSV/276. The RSV/276 arm closed early due to an excess of mild cough in another study. The proportion (95% CI) of children experiencing at least 1 solicited adverse event during the 28 days after inoculation was 55% (32%, 77%) in RSV/ΔNS2/Δ1313/I1314L, 40% (19%, 64%) in RSV/6120/ΔNS2/1030s, 71% (29%, 96%) in RSV/276, and 55% (32%, 77%) in placebo. Events were mostly Grade 1 and often associated with other viruses. The proportion of children with ≥4-fold increase in serum RSV-neutralizing antibody titer in each vaccine arm (>70%) was significantly greater than the placebo arm (15%). Conclusions: RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s had excellent safety and immunogenicity;assessment of RSV/276 was limited by the small sample size. RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s were deemed suitable for further evaluation. Clinical Trials Registration: NCT03916185.
Funding Information
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Network
  • National Institute of Allergy and Infectious Diseases
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute of Mental Health
  • National Institutes of Health (UM1AI068632)
  • National Institutes of Health (UM1AI068616)
  • National Institutes of Health (UM1AI106716)
  • National Institutes of Health (AI000326-43)
  • National Institute of Child Health and Human Development (HHSN275201800001I)
  • Norges Idrettshøgskole
  • National Institute of Allergy and Infectious Diseases (HHSN272200900010C)
  • National Institute of Allergy and Infectious Diseases (75N93019D00031)
  • Sanofi Australia
  • National Center for Advancing Translational Sciences (TR004399)
  • U.S. Department of Health and Human Services

This publication has 26 references indexed in Scilit: